ENHERTU Plus Pertuzumab Granted U.S. Breakthrough Therapy Status for HER2+ Metastatic Breast Cancer Read more
Lynozyfic (linvoseltamab-gcpt) Granted FDA Accelerated Approval for Relapsed/Refractory Multiple Myeloma Read more